Figure 3. Cost-effectiveness acceptability curves. Panels A and B show the healthcare system perspective; C and D show the societal perspective. In B and D, we assumed that half of the time (Q = 50%) the emergent pandemic strain would be would be of a subtype to which the stockpiled vaccine offered no protection. We did not explore the use of such a vaccine in subsequent pandemics. Costs and life-years discounted at 5% annually. A$, Australian dollars; LYS, life-year saved.